RVNC - CONSENSUS CO - Revance Therapeutics

Revance Therapeutics (RVNC) develops innovative dermatological products leveraging exclusive patents and strict FDA oversight. However, high promotion costs and potential therapy complications create significant challenges. This price chart reflects the asset's dynamics, where the indicator stands at . Future quotes will be impacted by dumping in the injectables segment, forcing the company to lower the cost of Daxxify for clinics.

This indicator represents the weighted average target price of Revance Therapeutics (RVNC) shares, calculated based on daily valuation revisions from leading investment houses to determine fundamental growth potential. The price action of the investment houses' weighted average target serves as a risk mitigation tool, reflecting market expectations for the productivity of the RVNC innovation cycle and the upcoming clinical trial results for Daxxify.